SCHEMBL20162154

SCHEMBL20162154

CC(C)(C)OC(=O)n1cnc(NC(=O)c2cnc3c(c2)CCN(C(=O)O)C3)c1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAP3K5 Q99683 5/20 0.37
MAPT P10636 2/20 0.36
ESR2 Q92731 1/20 0.36
NR1H2 P55055 1/20 0.35
GRAMD1A Q96CP6 1/20 0.34
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33
MAPK1 P28482 1/20 0.33
NAMPT P43490 1/20 0.32
USP30 Q70CQ3 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
SLC34A1 Q06495 1/20 0.32
PIK3CA P42336 1/20 0.32
MTOR P42345 1/20 0.32
GCK P35557 1/20 0.32
RAF1 P04049 1/20 0.32
BRAF P15056 1/20 0.32
RORC P51449 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20364366 0.94 MAPT (0.41) MAP3K5MAPTESR2NR1H2GRAMD1A
SCHEMBL20162157 0.87 ESR2 (0.48) MAP3K5ESR2NR1H2
SCHEMBL20169979 0.84 ESR2 (0.43) MAP3K5MAPTESR2NR1H2GRAMD1A
SCHEMBL20364368 0.83 MAP3K5 (0.40) MAP3K5MAPTESR2NR1H2GRAMD1A
SCHEMBL20364362 0.81 ESR2 (0.55) MAP3K5MAPTESR2NR1H2GRAMD1A
SCHEMBL20364367 0.78 ESR2 (0.41) MAP3K5MAPTESR2NR1H2GRAMD1A
SCHEMBL20364335 0.78 MAP3K5 (0.38) MAP3K5MAPTESR2NR1H2GRAMD1A
SCHEMBL20364365 0.78 MAP3K5 (0.36) MAP3K5MAPTESR2NR1H2GRAMD1A
SCHEMBL721062 0.77 ESR2 (0.48) MAP3K5MAPTESR2NR1H2GRAMD1A
SCHEMBL20364348 0.76 MAP3K5 (0.41) MAP3K5ESR2GCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10294237-B2 Bicyclic heterocyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2019-05-21 US disclosed
US-20180194773-A1 BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2018-07-12 US disclosed
EP-3323809-A1 BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE Sumitomo Dainippon Pharma Co., Ltd. (JP) 2018-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10294237-B2 Bicyclic heterocyclic amide derivative NR0B1, NR2E1, NR0B2 MAP3K5 3026/4885MAPT 4815/4885ESR2 620/4885
US-20180194773-A1 BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE NR0B1, NR2E1, NR0B2 MAP3K5 3026/4885MAPT 4815/4885ESR2 620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.